BCR ligation selectively inhibits IgE class switch recombination
Listen to this summary
The authors aimed to determine whether B cell receptor (BCR) signaling selectively inhibits IgE class switch recombination (CSR). Their findings indicate that stronger BCR signaling correlates with reduced frequencies of IgE-switched B cells in both mice and human B cell cultures, suggesting that BCR signaling uniquely suppresses IgE CSR through mechanisms involving specific signaling pathways and cytokine interactions. This research highlights the potential role of BCR signaling in regulating IgE production, which has implications for understanding allergic diseases.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from The Journal of allergy and clinical immunology
View all →Jun 10, 2026 · The Journal of allergy and clinical immunology
The SPRR2A-CSTA Axis Drives IL-17A-Induced Squamous Metaplasia and Steroid Resistance in Allergic Rhinitis
Jun 9, 2026 · The Journal of allergy and clinical immunology
Antigen-Specific mRNA-LNP Therapy with mTOR Inhibition Promotes Treg Cells and Limits Allergy
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


